Bethany J Foster1,2,3, Mark M Mitsnefes4, Mourad Dahhou5, Xun Zhang5, Benjamin L Laskin6. 1. Research Institute of the McGill University Health Centre, bethany.foster@mcgill.ca. 2. Division of Nephrology, Department of Pediatrics, and. 3. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada. 4. Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; and. 5. Research Institute of the McGill University Health Centre. 6. Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
BACKGROUND AND OBJECTIVES: Individuals with ESRD have a very high risk of death. Although mortality rates have decreased over time in ESRD, it is unknown if improvements merely reflect parallel increases in general population survival. We, therefore, examined changes in the excess risk of all-cause mortality-over and above the risk in the general population-among people treated for ESRD in the United States from 1995 to 2013. We hypothesized that the magnitude of change in the excess risk of death would differ by age and RRT modality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used time-dependent relative survival models including data from persons with incident ESRD as recorded in the US Renal Data System and age-, sex-, race-, and calendar year-specific general population mortality rates from the Centers for Disease Control and Prevention. We calculated relative excess risks (analogous to hazard ratios) to examine the association between advancing calendar time and the primary outcome of all-cause mortality. RESULTS: We included 1,938,148 children and adults with incident ESRD from 1995 to 2013. Adjusted relative excess risk per 5-year increment in calendar time ranged from 0.73 (95% confidence interval, 0.69 to 0.77) for 0-14 year olds to 0.88 (95% confidence interval, 0.88 to 0.88) for ≥65 year olds, meaning that the excess risk of ESRD-related death decreased by 12%-27% over any 5-year interval between 1995 and 2013. Decreases in excess mortality over time were observed for all ages and both during treatment with dialysis and during time with a functioning kidney transplant (year by age and year by renal replacement modality interactions were both P<0.001), with the largest relative improvements observed for the youngest persons with a functioning kidney transplant. Absolute decreases in excess ESRD-related mortality were greatest for the oldest persons. CONCLUSIONS: The excess risk of all-cause mortality among people with ESRD, over and above the risk in the general population, decreased significantly between 1995 and 2013 in the United States.
BACKGROUND AND OBJECTIVES: Individuals with ESRD have a very high risk of death. Although mortality rates have decreased over time in ESRD, it is unknown if improvements merely reflect parallel increases in general population survival. We, therefore, examined changes in the excess risk of all-cause mortality-over and above the risk in the general population-among people treated for ESRD in the United States from 1995 to 2013. We hypothesized that the magnitude of change in the excess risk of death would differ by age and RRT modality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used time-dependent relative survival models including data from persons with incident ESRD as recorded in the US Renal Data System and age-, sex-, race-, and calendar year-specific general population mortality rates from the Centers for Disease Control and Prevention. We calculated relative excess risks (analogous to hazard ratios) to examine the association between advancing calendar time and the primary outcome of all-cause mortality. RESULTS: We included 1,938,148 children and adults with incident ESRD from 1995 to 2013. Adjusted relative excess risk per 5-year increment in calendar time ranged from 0.73 (95% confidence interval, 0.69 to 0.77) for 0-14 year olds to 0.88 (95% confidence interval, 0.88 to 0.88) for ≥65 year olds, meaning that the excess risk of ESRD-related death decreased by 12%-27% over any 5-year interval between 1995 and 2013. Decreases in excess mortality over time were observed for all ages and both during treatment with dialysis and during time with a functioning kidney transplant (year by age and year by renal replacement modality interactions were both P<0.001), with the largest relative improvements observed for the youngest persons with a functioning kidney transplant. Absolute decreases in excess ESRD-related mortality were greatest for the oldest persons. CONCLUSIONS: The excess risk of all-cause mortality among people with ESRD, over and above the risk in the general population, decreased significantly between 1995 and 2013 in the United States.
Authors: Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey Journal: N Engl J Med Date: 2012-11-03 Impact factor: 91.245
Authors: Matthew A Roberts; Kevan R Polkinghorne; Stephen P McDonald; Francesco L Ierino Journal: Am J Kidney Dis Date: 2011-04-02 Impact factor: 8.860
Authors: Anna Francis; David W Johnson; Anette Melk; Bethany J Foster; Katrina Blazek; Jonathan C Craig; Germaine Wong Journal: Clin J Am Soc Nephrol Date: 2020-02-19 Impact factor: 8.237
Authors: Jessica L Harding; Jedidiah I Morton; Jonathan E Shaw; Rachel E Patzer; Stephen P McDonald; Dianna J Magliano Journal: Nephrol Dial Transplant Date: 2022-09-22 Impact factor: 7.186
Authors: John S Thurlow; Megha Joshi; Guofen Yan; Keith C Norris; Lawrence Y Agodoa; Christina M Yuan; Robert Nee Journal: Am J Nephrol Date: 2021-03-22 Impact factor: 4.605
Authors: Anja Pfau; Theresa Ermer; Steven G Coca; Maria Clarissa Tio; Bernd Genser; Martin Reichel; Fredric O Finkelstein; Winfried März; Christoph Wanner; Sushrut S Waikar; Kai-Uwe Eckardt; Peter S Aronson; Christiane Drechsler; Felix Knauf Journal: J Am Soc Nephrol Date: 2021-07-19 Impact factor: 14.978